Swedish immunotherapy company Immunicum has broadened its cancer treatment focus with the addition of drug candidate DCP-001 thanks to the merger with Dutch biotech DCprime. Treating tumour recurrence is now a top priority for the company, and Immunicum’s CEO Erik Manting came by the BioStock Studio to talk more in depth about this new focus and how the addition of DCP-001 impacts Immunicum’s business strategy.
Watch the interview with Immunicum’s CEO Erik Manting in the link below.
Click here for a broader overview of Immunicum that includes another in-depth Q&A with CEO Erik Manting.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.